Ionis’s recent developments
As we discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.
Let’s take a look at Ionis’s most recent corporate developments and drug developments.
A few of the company’s recent developments include the following:
- On January 5, 2018, Akcea Therapeutics announced its initiation of a Phase 2b clinical study to evaluate the safety and efficacy of AKCEA-APOCIII-LRx for the treatment of patients with hypertriglyceridemia and established cardiovascular diseases. AKCEA-APOCIII-LRx is an antisense drug based on Ligand Conjugated Antisense technology.
- On December 21, 2017, Ionis announced the initiation of a Phase I clinical study evaluating IONIS-JBI1-2.5Rx for the treatment of patients with gastrointestinal immune disorder. Ionis also received a $5 million milestone payment from Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ) responsible for global development, regulatory, and commercialization activities for the drug IONIS-JBI1-2.5Rx.
- On December 19, 2017, Ionis and Biogen (BIIB) announced a new collaborative agreement for the identification of a new antisense oligonucleotide drug for the treatment of spinal muscular atrophy. Biogen holds the option to license therapies developed under this collaboration. It will also be responsible for the development and commercialization of these therapies.
- On December 18, 2017, Ionis announced its receipt of $45 million as a licensing fee from Roche following the clearance of their license agreement for the development and commercialization of IONIS-HTTRx for the treatment of Huntington’s disease under the Hart-Scott-Rodino Antitrust Improvements Act.